A Phase 2 Study to Evaluate the Safety, PK, and Exploratory PD of Tildacerfont in Children With CAH

  • STATUS
    Recruiting
  • participants needed
    20
  • sponsor
    Spruce Biosciences
Send
Updated on 16 September 2023
See if I qualify
21-ohd

Summary

An investigation of the safety of Tildacerfont in pediatric subjects with CAH.

Description

This is a study to evaluate the safety of Tildacerfont in pediatric subjects with CAH. Treatment will consist of 14 days of continuous dosing followed by safety follow up.

Details
Condition Congenital Adrenal Hyperplasia, 21-OHD
Treatment Tildacerfont
Clinical Study IdentifierNCT05128942
SponsorSpruce Biosciences
Last Modified on16 September 2023

Similar trials to consider

Browse trials for

21-ohd

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note